Kellgren Centre successfully recruits 500th patient onto lupus study
Last week the research team at the Kellgren Centre for
Rheumatology reached a key milestone in recruiting the 500th
patient onto the BILAG (British Isles Lupus Assessment Group)
Biologics Register study.
The BILAG BR study is an observational cohort study looking at
patients with lupus who are starting treatment with a biologic drug
or a conventional non-biologic therapy.
The aim of the study is to find out whether using biologics as
treatment for lupus is associated with an increased risk of
hospitalisation for infection, compared to lupus patients with
similar disease activity receiving conventional treatments. The
study will also look at the long-term efficacy of biological
therapies in the treatment of lupus.
Principal Investigator Professor Ian Bruce, Lead Clinician at
the Kellgren Centre said:
"Thanks to the hard work of the research and clinical staff at
the Kellgren Centre, we have been able to recruit a large number of
patients onto this study. Observational cohort studies are
important to ensure we are using the most effective treatments that
are available for our patients."